Skip to content
Search

Latest Stories

UK in talks with Roche on 'game changer' Covid-19 antibody tests

Britain is in talks with Swiss drugmaker Roche Holding AG on rolling out an accurate Covid-19 antibody test that it said could be a 'game changer' on getting the world's fifth largest economy back to work.

The novel coronavirus, which emerged in China, has propelled the world towards the sharpest recession in centuries with many people isolating at home as governments grapple with one of the biggest health crises since the 1918 influenza epidemic.


The British government said it was talking with Roche on rolling out its test after a Public Health England laboratory at Porton Down, in Wiltshire, concluded it had 100 per cent specificity. That means it can detect antibodies to the exact disease rather than similar ones.

"This has the potential to be a game changer," said Edward Argar, Britain's junior health minister.

"We are now moving as fast as we can to discuss with Roche purchasing of those but I can't give you an exact date when we'll be able to start rolling them out."

The Roche test received a conformity assessment, known as Conformité Européenne, or CE mark, from the European Union on April 28 and received Emergency Use Authorization from the US Food and Drug Administration on May 2.

Before the Porton Down laboratory's results, the United Kingdom had said no Covid-19 antibody test was accurate enough to use.

"This is a very positive development because such a highly specific anti-body test is a very reliable marker of past infection," said John Newton, national coordinator of the UK Coronavirus Testing Programme.

"Scientific experts at PHE Porton Down carried out an independent evaluation of the new Roche SARS-CoV-2 serology assay in record time, concluding that it is a highly specific assay with specificity of 100 per cent."

Roche said late on Wednesday (13) it was in talks with the National Health Service and the UK government about a phased roll-out of antibody test kits as soon as possible and would be able to provide hundreds of thousands of the test kits per week.

"The test requires a blood sample to be taken by a qualified healthcare professional and processed in a laboratory," Roche said, adding that it was one of the most accurate tests on the market with over 99.8 specificity.

"This level of accuracy is vitally important because there are a number of viruses with very similar antibodies to Covid-19, including the common cold, and other SARS strains, which can produce a positive result in some less accurate antibody tests."

The Telegraph, which first reported the findings, said the government was in negotiations with Roche to buy millions of kits.

Similar antibody tests have also been developed by companies including U.S.-based Abbott Laboratories and Italy’s DiaSorin.

Unlike tests to diagnose diseases, antibody tests show who has been infected, although it is not yet clear whether that confers permanent immunity.

(Reuters)

More For You

Cargo plane unloading pharmaceuticals at US airport amid tariff concerns and stockpiling

Imports jumped in particular from Ireland, the top drug exporter to the US

Pic credit: iStock

Pharma imports to US surged in March as drugmakers look to avoid tariffs

Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential US tariffs on their products, which have historically been exempt from such fees.

Total imports of pharmaceutical products exceeded $50 billion in the month - the equivalent of 20 per cent of all pharmaceutical imports in 2024, according to data from a U.S. Commerce Department report on Tuesday.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less